當(dāng)前位置：臺州市科瑞生物技術(shù)有限公司>>前列腺素系列>>伊洛前列素 Iloprost

伊洛前列素 Iloprost

返回列表頁

參考價(jià)

面議

具體成交價(jià)以合同協(xié)議為準(zhǔn)

產(chǎn)品型號cas 78919-13-8

品牌其他品牌

廠商性質(zhì)生產(chǎn)商

所在地臺州市

在線詢價(jià) 收藏產(chǎn)品

聯(lián)系方式：金崇光查看聯(lián)系方式

更新時(shí)間：2020-08-28 15:09:23瀏覽次數(shù)：436次

聯(lián)系我時(shí)，請告知來自制藥網(wǎng)

產(chǎn)品分類 品牌分類

  前列腺素系列
  獸藥原料藥
  其他

  其他品牌

臺州市科瑞生物技術(shù)有限公司

經(jīng)營模式：生產(chǎn)廠家

商鋪產(chǎn)品：182條

所在地區(qū)：浙江臺州市

聯(lián)系人：金崇光（總經(jīng)理）

詢價(jià) 給他留言

產(chǎn)品簡介

CAS號	78919-13-8	產(chǎn)地	國產(chǎn)
級別	醫(yī)用級

伊洛前列素Iloprost （ZK 36374）是一種前列環(huán)素PGI2的合成類似物.

詳細(xì)介紹

伊洛前列素Iloprost (ZK 36374)是一種前列環(huán)素PGI2的合成類似物.

Iloprost (ZK 36374) is a synthetic analogue of prostacyclin PGI2. Target: Iloprost is a stable prostacyclin analog commonly employed in the treatment of peripheral vascular disease and also indicated in the treatment of patients affected by systemic sclerosis (SSc) in the presence of severe Raynaud's phenomenon (RP). [1] Iloprost dilates systemic and pulmonary arterial vascularbeds. Iloprost also affects platlet aggregation but the relevance of this effect to the treatment of pulmonary hypertension is unknown. The two diastereoisomers of iloprost differ in their potency in dilating blood vessels, with the 4S isomer substantially more potent than the 4R isomer.[2] Iloprost is a stable carbacyclin derivative of prostacyclin, was studied during electrically-induced coronary artery thrombosis in the open chest anesthetized pig. Infusion of ZK 36374 (100 ng/kg/min, n = 6) had no effect on heart rate and cardiac output, but caused a 20% reduction in mean arterial blood pressure by peripheral vasodilation. In animals receiving solvent or no drug prior to thrombosis induction, the time to occlusive coronary artery thrombosis (TOT) was 30 +/- 2 minutes (mean +/- SEM, n = 17). Pretreatment with an i.v. infusion of ZK 36374 (100 ng/kg/min) prolonged TOT by 50% to 47 +/- 7 minutes (p less than 0.005, n = 6). This prolongation of TOT was not due to the lower blood pressure in the ZK 36374 group, as dihydralazine in a dose that lowered arterial blood pressure to the same extent had no effect on TOT (32 +/- 4 minutes, n = 4). The results indicate that ZK 36374 may be useful in delaying (or preventing) occlusive coronary artery thrombi.